BRAF and melanoma: Conversely, while the vast majority of patients with BRAF-mutant melanoma has objective responses or temporary stable disease when treated with a BRAF inhibitor, they inevitably relapse, almost always in the first 1–2 years of therapy due to acquired resistance (3).